Effect of Posttreatment Residual Functional Mitral Regurgitation on Patient Outcomes

In the COAPT trial, residual MR was associated with a higher rate of death or heart failure hospitalization and worse quality of life.

The manufacturer-supported, randomized COAPT trial demonstrated improved survival, fewer heart failure hospitalizations, and better quality of life with transcatheter edge-to-edge repair (TEER) of secondary (functional) mitral regurgitation (MR) compared with guideline-directed medical therapy (GDMT) only (NEJM JW Cardiol Nov 2018 and N Engl J Med 2018; 379:2307). In this secondary analysis, investigators examined the relationship between residual MR and outcomes with both TEER and GDMT alone.

Residual MR at 30 days was assessed in 534 trial patients (87%); severe MR was present in 35% and moderate in 23%, with higher percentages in the control (GDMT-only) trial arm than the TEER arm. Patients with severe residual MR had a substantially high…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)